We are live on ! Find out more
AYTU icon

AYTU BioPharma

64 hedge funds and large institutions have $48.3M invested in AYTU BioPharma in 2021 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 23 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

440% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 5

283% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 6

142% more call options, than puts

Call options by funds: $368K | Put options by funds: $152K

88% more capital invested

Capital invested by funds: $25.7M → $48.3M (+$22.5M)

52% more funds holding

Funds holding: 4264 (+22)

0.11% more ownership

Funds ownership: 1.25%1.36% (+0.11%)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
64
Holders Change
+22
Holders Change %
+52.38%
% of All Funds
1.12%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
27
Increased
23
Reduced
6
Closed
5
Calls
$368K
Puts
$152K
Net Calls
+$216K
Net Calls Change
+$216K

AYTU Hedge Fund Activity: Q1 2021 in Review

64 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q1 2021, worth a combined $48.3M — up 88% from $25.7M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new AYTU positions and 5 closed out — a net gain of 22 holders — while 23 added to existing stakes and 6 trimmed.

The largest buyer was BlackRock, adding an estimated $10.2M. The largest seller was Stonepine Capital Management, cutting an estimated $8.22M.

  • 64 institutional investors held AYTU BioPharma (AYTU) as of Q1 2021, up from 42 in Q4 2020.
  • Funds reported $48.3M of AYTU BioPharma stock for Q1 2021, up 88% quarter-over-quarter.
  • 27 funds opened new AYTU BioPharma positions in Q1 2021 and 5 closed out, a net change of +22 holders.
  • The largest AYTU BioPharma buyer in Q1 2021 was BlackRock, an estimated $10.2M added.
  • The largest AYTU BioPharma seller in Q1 2021 was Stonepine Capital Management, an estimated $8.22M sold.

Based on aggregated 13F filings for Q1 2021.